CLINICAL ROLE -
ASHP Midyear: 2025 GOLD Report Updates Highlight Cardiovascular Risks, New Therapies for COPD Patients
The 2025 GOLD Report emphasizes the importance of tailoring combination treatments based on patient factors like eosinophil counts and exacerbation history.
Watch
ASHP Midyear: Optimizing IVIG Therapy for BK Nephropathy in Kidney Transplant Patients Can Improve Outcomes
Pharmacists can optimize IVIG treatment for BK nephropathy in kidney transplant recipients by educating providers and monitoring for infusion reactions.
ASHP Midyear: Vaccination Among Older Adults Prevents Severe RSV Infections
Pharmacists are essential in preventing the significant health and economic burden of respiratory syncytial virus (RSV) infections in older adults through vaccination.
Read More
ASHP Midyear: New Oral Treatment, Antibody Drug Conjugates Offer Additional Options for Breast Cancer
Pharmacists identify appropriate patients for new oral and antibody drug conjugate treatments and provide counseling to help patients navigate the evolving treatment landscape.
ASHP Midyear: Compounding Medications Provide Personalized Options for Patients
Compounding pharmacies play a vital role in meeting the unique needs of patients, but pharmacists must adhere to strict safety standards and regulations.
ASHP Midyear: Real-World Data Collection Helps to Facilitate Successful Biosimilar Adoption
The evolving regulatory policies around biosimilar interchangeability is crucial for driving successful biosimilar adoption in the marketplace.
ASHP Midyear: Automated Compounding Workflows and Comprehensive Record-Keeping Reduce Errors
Pharmacy errors can happen due to manual processes, but they can be mitigated through adoption of automated IV workflow technology and comprehensive compounding records.
ASHP Midyear: Food Insecurity Impacted Hypertension for Patients, Especially in Rural Areas
Food insecurity in rural communities can affect hypertension, but pharmacists can mitigate the impact by educating themselves on nutrition options for low-income individuals.
ASH 2024: Nuvisertib Demonstrates Durable Response in Relapsed/Refractory Myelofibrosis
Firas El Chaer, MD, discusses newly-presented data at ASH demonstrating nuvisertib's effectiveness in myelofibrosis.
ASHP Midyear: Pharmacist Emphasizes Individualized Approach to Antiplatelet Therapy Management
Snehal Bhatt discusess the need to individualize antiplatelet therapy decisions based on a comprehensive assessment of each patient's unique risk factors for thrombosis and bleeding.
SABCS 2024: The Persistent Association Between Obesity and Breast Cancer Outcomes
Obesity is associated with increased distant recurrence and breast cancer mortality in all types of early-stage breast cancer.
ASHP Midyear: Overcoming Staffing Challenges and Ensuring Medication Access in Rural Pharmacies
Rural pharmacies and hospitals face unique challenges in maintaining adequate staffing and drug supply inventory to serve patients who often travel long distance.
SABCS 2024: Identifying High-Risk Women for Targeted Breast Cancer Prevention Through AI-Powered Mammography Analysis
AI-powered analysis of mammography images can identify women at high long-term risk of breast cancer, enabling targeted prevention strategies.
SABCS 2024: Anthracyclines May Improve Survival in High-Risk Breast Cancer, But Risks Must Be Weighed
Adding anthracyclines to chemotherapy may improve survival in high-risk breast cancer patients.
ASHP Midyear: Pharmacists Play Key Role in Addressing Depression in Women Through Medication Management
Pharmacists can make a significant impact by providing medication management, promoting nonpharmacologic approaches, supporting patients through life transitions.
ASHP Midyear: Pharmacy Compounding Requires Ensuring Quality, Safety, and Preparedness
Daily operational tasks and quality assurance measures in pharmacy compounding ensures patient safety and maintains compliance.
ASH 2024: Expert Discusses Challenges, Future Research Opportunities With Bispecific Antibodies in Multiple Myeloma
Ira Zackon, MD, explains where future research lies regarding the implementation of bispecific antibodies in community oncology settings.
SABCS 2024: Camizestrant Shows Promise in Combination with Ribociclib for Advanced Breast Cancer
The novel camizestrant-ribociclib combination demonstrated encouraging data in advanced, pre-treated ER+/HER2- breast cancer.
SABCS 2024: Unlocking the Potential of Breast Cancer Prevention Vaccines
Breast cancer prevention vaccines could have significant positive societal impact by reducing cancer diagnoses.
ASHP Midyear: Pharmacists Play Key Role in Addressing Concerns and Fostering Adoption of Biosimilars
Pharmacists can help drive the successful adoption of biosimilars by developing educational programs to address provider and patient concerns.
SABCS 2024: Combination of Elacestrant and Abemaciclib Shows Promising Progression-Free Survival in ER+/HER2- Advanced Breast Cancer
The combination of elacestrant and abemaciclib showed promising 8.7-month progression-free survival in ER+, HER2- advanced breast cancer, including in patients with ESR1 mutations.
ASHP Midyear: Pharmacists Play Crucial Role in Skin Care Recommendations
Pharmacists are crucial skin care experts and should counsel patients on the importance of adjunct therapies like moisturizers and sunscreen when using certain medications.
SABCS 2024: Harnessing the Power of Tumor-Infiltrating Lymphocytes to Revolutionize Breast Cancer Treatment
The assessment of tumor-infiltrating lymphocytes can provide valuable insights to guide personalized treatment decisions for breast cancer patients.
SABCS 2024: Risk-Reducing Surgeries Linked to Improved Survival in Young BRCA Carriers with Breast Cancer
Both risk-reducing mastectomy and salpingo-oophorectomy were associated with significant improvements among young BRCA carriers with breast cancer.
SABCS 2024: Using Tumor Immune Profiles to Guide Neoadjuvant Therapy in Young Breast Cancer Patients
Assessing pre-treatment TIL levels in young breast cancer patients could help predict response to neoadjuvant chemotherapy.
ASHP Midyear: Rural Health Care Barriers Impact Medication Adherence and Hypertension Management
Rural patients face significant barriers to health care access and affordability that contribute to poor hypertension management.
SABCS 2024: Imlunestrant Monotherapy and Combination with Abemaciclib Show Promising Efficacy and Safety in Metastatic Breast Cancer
Komal Jhaveri MD, FACP, shares that the combination of imlunestrant plus abemaciclib further improved progression-free survival compared to imlunestrant alone.
ASHP Midyear: Dose Rounding Strategies Minimize Waste and Maintain Patient Safety
Dose rounding within an acceptable range can provide cost savings and minimize waste, but requires careful interprofessional collaboration and patient education.
SABCS 2024: The Role of ESR1 Mutation Testing and Combination Strategies in Metastatic HR+/HER2- Breast Cancer
Virginia Kaklamani, MD, DSc, shares the role of ESR1 mutation testing and combination strategies to optimize endocrine therapy in patients with metastatic HR+/HER2- breast cancer.
ASHP Midyear: Technology Helps Leverage Medication Management, IV Compounding
Pharmacists are essential members of the patient care team, leveraging technology like automated IV compounding to standardize processes.